Audentes Therapeutics (NASDAQ:BOLD) has been assigned a $37.00 price target by analysts at HC Wainwright in a report released on Thursday, January 4th. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential downside of 1.25% from the company’s current price.
Other equities analysts have also issued reports about the stock. Bank of America reaffirmed a “buy” rating and issued a $33.00 price target (up from $23.00) on shares of Audentes Therapeutics in a report on Friday, September 22nd. William Blair began coverage on shares of Audentes Therapeutics in a research note on Tuesday, October 17th. They set an “outperform” rating and a $35.00 price objective for the company. Raymond James Financial began coverage on shares of Audentes Therapeutics in a research report on Thursday, October 12th. They set a “market perform” rating for the company. BMO Capital Markets began coverage on shares of Audentes Therapeutics in a research report on Tuesday, December 5th. They set an “outperform” rating and a $35.00 target price for the company. Finally, ValuEngine cut shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Audentes Therapeutics has an average rating of “Buy” and an average price target of $35.00.
Shares of Audentes Therapeutics (BOLD) traded up $1.30 during midday trading on Thursday, reaching $37.47. 344,682 shares of the company’s stock traded hands, compared to its average volume of 406,481. The company has a market capitalization of $1,079.87, a P/E ratio of -10.74 and a beta of -0.21. Audentes Therapeutics has a twelve month low of $13.90 and a twelve month high of $41.80.
Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.88). equities research analysts predict that Audentes Therapeutics will post -3.5 EPS for the current year.
In other news, Director Louis G. Lange sold 18,000 shares of the company’s stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $30.88, for a total value of $555,840.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Mary Newman sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $26.84, for a total transaction of $268,400.00. The disclosure for this sale can be found here. Insiders sold a total of 36,000 shares of company stock worth $1,052,480 over the last quarter. 47.30% of the stock is currently owned by company insiders.
Several large investors have recently made changes to their positions in BOLD. Schwab Charles Investment Management Inc. increased its position in shares of Audentes Therapeutics by 139.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 25,600 shares of the biotechnology company’s stock valued at $490,000 after purchasing an additional 14,900 shares during the last quarter. Rhumbline Advisers purchased a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at approximately $252,000. State of Wisconsin Investment Board purchased a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at approximately $210,000. Bank of New York Mellon Corp increased its position in shares of Audentes Therapeutics by 180.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 52,900 shares of the biotechnology company’s stock valued at $1,012,000 after purchasing an additional 34,057 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of Audentes Therapeutics by 31.5% in the 2nd quarter. Alliancebernstein L.P. now owns 640,654 shares of the biotechnology company’s stock valued at $12,256,000 after purchasing an additional 153,617 shares during the last quarter. 78.95% of the stock is currently owned by institutional investors.
WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/audentes-therapeutics-bold-given-a-37-00-price-target-by-hc-wainwright-analysts.html.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.